Zhang lab unlocks crystal structure of new CRISPR/Cas9 genome editing tool

Paul Goldsmith, August 27th, 2015

In a paper published today in Cell researchers from the Broad Institute and University of Tokyo revealed the crystal structure of the Staphylococcus aureus Cas9 complex (SaCas9)—a highly efficient enzyme that overcomes one of the primary challenges to in vivo mammalian genome editing.

Read More

New insights on an old virus

Angela Page, August 13th, 2015

Between 2013 and 2015, an outbreak of Ebola virus killed more than 11,000 people. Broad Institute researchers quickly deployed real-time sequencing efforts that confirmed that the virus was primarily spreading through human-to-human contact rather than between animals and humans and that the viral genome was mutating. This work had a profound impact on how public health officials diagnosed the disease and developed strategies to contain it.

Read More

From Barrett’s to cancer

Veronica Meade-Kelly, July 20th, 2015

What: A new study by researchers from the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital suggests that esophageal adenocarcinoma (EAC) progresses differently than previously suspected.

Read More

Development in reverse: A better model of human induced pluripotency

Leah Eisenstadt, July 16th, 2015

What: Studying the reprogramming process in human cells is now easier and more reliable, thanks to work by a team of scientists led by Broad Institute researcher Tarjei Mikkelsen. The team designed an improved method for generating human induced pluripotent stem (iPS) cells in the lab that reduces variability. The system enables a high-resolution look at the intermediate cellular and molecular changes taking place as somatic cells are reprogrammed to become iPS cells, something much more difficult to study before this new model.

Read More

Letting the knowledge flow: Firehose, FireBrowse & FireCloud

Raleigh McElvery, July 13th, 2015

It's been said that getting an education from MIT is like taking a drink from a fire hose. At the Broad Institute of MIT and Harvard a similar ethos prevails, and is particularly evident in the aptly named cancer analysis pipeline, Firehose.

Read More

Unraveling an age-old antibiotic mystery

Angela Page, July 9th, 2015

In the 1950s, an early clinical study compared the efficacy of a bactericidal antibiotic, which kills bacteria, to a combination with a bacteriostatic antibiotic, which only stops bacterial cell growth. The study revealed that the bactericidal antibiotic was not as effective at killing bacteria when used in combination with the bacteriostatic antibiotic. The bacteriostatic drug seemed to have a dominant effect, but the underlying biological mechanisms of this phenomenon were never unraveled.

Read More

A cancer drug that wears many hats

Leah Eisenstadt, July 1st, 2015

Nearly a decade ago, the FDA approved the drug lenalidomide to treat patients with deletion-5q myelodysplastic syndrome (del(5q) MDS), a cancer of the myeloid cells in the bone marrow that form several types of blood cells. In this condition, some bone marrow cells are missing a portion of chromosome 5 – hence, the “del(5q)” – on one copy of their genome (the human genome has two copies of each chromosome, one from each parent), and this deletion causes malignant cells to grow unchecked.

Read More

Five (more) questions for David Root

Veronica Meade-Kelly, June 12th, 2015

Four years ago, David Root talked with us about the fundamentals of RNA interference (RNAi) technology. But, since then, the group that Root oversees – Broad’s erstwhile RNAi Platform – has taken on a new identity: it’s now known as the Genetic Perturbation Platform (GPP).

Read More

Wall of sticky notes fuels genomics at Broad

Leah Eisenstadt, June 3rd, 2015

The Broad Institute is designed for collaboration. Visitors will notice walls of glass that promote transparency, “living rooms” with casual seating for informal meetings, and writable, “whiteboard walls” stocked with dry erase markers for spontaneous brainstorming sessions. Some of these writable walls sport chemical formulas or structures and others detail new hypotheses.

Read More

Five Questions with Jay Bradner

Paul Goldsmith, May 29th, 2015

As associate director of the Broad’s Center for the Science of Therapeutics (CSofT), award-winning hematologist at Dana-Farber Cancer Institute, and a recognized pioneer in open-source drug discovery (not that he would admit to it), Jay Bradner is something of a rock star in the field of chemical biology.

Read More